Pharma/fine chemicals roundup—26 April 2016
3:06 AM MDT | April 26, 2016 | By DEEPTI RAMESH
PCI forms cGMP advanced polymer development and manufacturing unit
PCI Synthesis (Newburyport, MA), a manufacturer of new chemical entities, generic active pharmaceutical ingredients (APIs), and other specialty chemical products, has formed a cGMP advanced polymer development and manufacturing group.
The group is currently developing and manufacturing more than a dozen advanced polymer-based projects, including nano-polymer particle technologies, combination API and polymer technologies and medical-grade coatings. PCI is the only contract manufacturing organization (CMO) in North America that does both developing and manufacturing, the company says.
“PCI Synthesis is the only CMO in Massachusetts doing this kind of advanced cGMP polymer manufacturing, which is a big advantage for local life sciences and pharma firms, since we're able to collaborate with them and their projects onsite,” says PCI president and CEO Ed Price.
Johnson Matthey and Domainex join forces
Johnson Matthey and Domainex (Cambridge, UK), a small-molecule drug discovery service company, have announced that they will collaborate to offer integrated small molecule pharmaceutical discovery and development services, from pharmaceutical discovery to clinical development. Domainex provides small molecule drug discovery services that complement the services provided by Johnson Matthey.
Companies will be able to access Domainex’s target-to-lead identification capabilities and then use Johnson Matthey for process development and scale-up. Discovery and development time and risk can be greatly minimized, the partners say, as all activities will be located in the Cambridge area.
Lubrizol’s Particle Sciences unit adds commercial manufacturing capacity
Particle Sciences (Bethlehem, PA), part of Lubrizol LifeSciences, is adding commercial drug product manufacturing capacity at its facility at Bethlehem. The expansion will include both sterile and non-sterile capacity with complete lyophilization and filling operations. The facility will be tailored for nano-milling and other complex processes, Lubrizol says. Particle Sciences is a provider of drug development services. Lubrizol acquired Particle Sciences in September 2015.
“As part of our plans for continued growth in this market, we have accelerated the commercial expansion plans at Particle Sciences. The work has already begun, and we plan to be operational in early 2017 with some of the capacity already spoken for by clients with whom we are currently developing products,” says Mark Mitchnick, chief medical officer at Lubrizol LifeSciences and CEO of Particle Sciences.
JSR forms life sciences division
JSR (Tokyo, Japan) has formed a biotechnology-focused business unit, JSR Life Sciences (JLS), which will focus on providing downstream bioprocessing materials for pharmaceutical manufacturing and diagnostics and research products. The formation of JLS is a part of JSR’s strategy to leverage its material and polymer expertise to expand into the life sciences industry in the two major industry categories of bioprocessing and diagnostic and research products.
The unit will be led by Eric Johnson, who will assume responsibility of all operations as senior executive officer of JSR and head of JLS. Johnson will also lead JLS in integrating the global operations of the United States, Europe, Asia and Japan.
Allergan invests $200 million to expand Texas facility
Allergan (Dublin) has broken ground on a $200-million expansion of its Waco, TX facility. The expansion will add a new raw material dispensary, an automated bulk formulation suite and ten new production lines as well as warehousing space. Upon completion, the Waco facility will be capable of producing more than 40 different product formulations and will increase its production capacity by more than 50%. The construction, commissioning and validation of the facility expansion and production processes are expected to be completed by 2020. Allergan's Waco facility is the company's flagship manufacturing facility for its leading eye care products. The expansion is expected to add approximately 100 full-time jobs, with the potential for the expanded operations adding as many as 250 full-time jobs as the facility reaches full utilization.